Grimes & Company’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.4M Buy
805,088
+9,806
+1% +$257K 0.42% 50
2026
Q1
$22.3M Buy
795,282
+5,332
+0.7% +$142K 0.62% 32
2025
Q4
$19.7M Buy
789,950
+684,303
+648% +$17.3M 0.47% 39
2025
Q3
$2.69M Buy
105,647
+7,875
+8% +$194K 0.07% 159
2025
Q2
$2.37M Buy
97,772
+2,089
+2% +$48.7K 0.06% 154
2025
Q1
$2.42M Buy
95,683
+1,854
+2% +$48.5K 0.08% 134
2024
Q4
$2.49M Sell
93,829
-4,097
-4% -$111K 0.07% 137
2024
Q3
$2.83M Buy
97,926
+4,969
+5% +$145K 0.08% 122
2024
Q2
$2.6M Buy
92,957
+4,915
+6% +$135K 0.08% 123
2024
Q1
$2.44M Sell
88,042
-12,029
-12% -$334K 0.08% 126
2023
Q4
$2.88M Buy
100,071
+14,488
+17% +$438K 0.1% 112
2023
Q3
$2.84M Sell
85,583
-456
-0.5% -$16.1K 0.11% 105
2023
Q2
$3.16M Sell
86,039
-3,640
-4% -$142K 0.11% 101
2023
Q1
$3.66M Buy
89,679
+8,113
+10% +$350K 0.15% 94
2022
Q4
$4.18M Buy
81,566
+824
+1% +$39.5K 0.18% 96
2022
Q3
$3.53M Buy
80,742
+95
+0.1% +$4.62K 0.18% 90
2022
Q2
$4.23M Buy
80,647
+141
+0.2% +$7.18K 0.21% 90
2022
Q1
$4.17M Sell
80,506
-55
-0.1% -$2.85K 0.22% 95
2021
Q4
$4.76M Sell
80,561
-418
-0.5% -$20.7K 0.22% 87
2021
Q3
$3.48M Sell
80,979
-1,097
-1% -$48.6K 0.15% 99
2021
Q2
$3.21M Sell
82,076
-3,725
-4% -$145K 0.14% 100
2021
Q1
$3.11M Buy
85,801
+9,691
+13% +$344K 0.15% 99
2020
Q4
$2.8M Sell
76,110
-3,064
-4% -$112K 0.15% 100
2020
Q3
$2.76M Buy
79,174
+413
+0.5% +$14.5K 0.18% 96
2020
Q2
$2.44M Buy
78,761
+98
+0.1% +$3.33K 0.17% 95
2020
Q1
$2.44M Buy
78,663
+5,195
+7% +$177K 0.22% 83
2019
Q4
$2.73M Sell
73,468
-3,824
-5% -$136K 0.18% 96
2019
Q3
$2.63M Buy
77,292
+55
+0.1% +$2K 0.19% 92
2019
Q2
$3.17M Sell
77,237
-427
-0.5% -$17K 0.24% 83
2019
Q1
$3.13M Sell
77,664
-43
-0.1% -$1.72K 0.25% 85
2018
Q4
$3.22M Sell
77,707
-4,762
-6% -$198K 0.31% 70
2018
Q3
$3.45M Buy
82,469
+1,217
+1% +$46.9K 0.28% 76
2018
Q2
$2.8M Sell
81,252
-604
-0.7% -$20.6K 0.25% 83
2018
Q1
$2.76M Buy
81,856
+11,132
+16% +$383K 0.27% 82
2017
Q4
$2.43M Buy
70,724
+9,636
+16% +$329K 0.23% 81
2017
Q3
$2.07M Sell
61,088
-100
-0.2% -$3.21K 0.22% 82
2017
Q2
$1.95M Sell
61,188
-183
-0.3% -$5.77K 0.22% 83
2017
Q1
$1.99M Sell
61,371
-232
-0.4% -$7.32K 0.22% 83
2016
Q4
$1.9M Buy
61,603
+7,770
+14% +$237K 0.22% 87
2016
Q3
$1.73M Sell
53,833
-3,235
-6% -$108K 0.23% 87
2016
Q2
$1.91M Buy
57,068
+3,301
+6% +$105K 0.25% 87
2016
Q1
$1.51M Buy
53,767
+1,660
+3% +$47.4K 0.19% 86
2015
Q4
$1.6M Sell
52,107
-1,562
-3% -$49.1K 0.22% 84
2015
Q3
$1.6M Sell
53,669
-174
-0.3% -$5.58K 0.21% 85
2015
Q2
$1.71M Buy
53,843
+1,568
+3% +$51.1K 0.24% 82
2015
Q1
$1.73M Sell
52,275
-2,956
-5% -$94K 0.41% 70
2014
Q4
$1.63M Buy
55,231
+1,264
+2% +$36.2K 0.42% 72
2014
Q3
$1.51M Buy
53,967
+1,336
+3% +$37.5K 0.4% 73
2014
Q2
$1.48M Buy
52,631
+3,852
+8% +$110K 0.39% 73
2014
Q1
$1.49M Sell
48,779
-85
-0.2% -$2.53K 0.42% 71
2013
Q4
$1.42M Buy
48,864
+4,331
+10% +$126K 0.42% 68
2013
Q3
$1.21M Buy
44,533
+5,067
+13% +$138K 0.41% 67
2013
Q2
$1.05M Buy
+39,466
New +$1.09M 0.38% 68

Other funds holding PFE

Grimes & Company's PFE Position: Q2 2026 in Review

Grimes & Company increased its Pfizer (PFE) stake by 1.2% in Q2 2026, buying an estimated $257K and bringing the position to 805,088 shares worth $19.4M. The position accounts for 0.42% of the portfolio, ranked #50.

Grimes & Company first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $22.3M in Q1 2026. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Grimes & Company held 805,088 shares of Pfizer worth $19.4M as of Q2 2026.
  • Grimes & Company bought 9,806 Pfizer shares in Q2 2026, an estimated $257K.
  • Pfizer made up 0.42% of Grimes & Company's portfolio in Q2 2026, its #50 holding.
  • Grimes & Company first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Grimes & Company's Pfizer position peaked at $22.3M in Q1 2026.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.